Ethernabe is a seasoned player in the RNA technology industry, boasting over three decades of experience. The company primarily serves pharmaceutical and biotech companies, both emerging and established, that have an interest in RNA therapeutics. Ethernabe's business model revolves around providing professional partnership and support for start-up, early stage, and late stage projects. They do this by leveraging their proprietary platforms in RNA chemistry, LNP formulation, and Process Technology.

The company's proprietary platforms are designed to help drive new pipeline development or resolve manufacturing challenges for their partners. They have developed innovative LNP platforms tailored for specific routes of administration such as intravenous (IV), intra-tumoral (IT), and intramuscular (IM), which allows for better targeted biodistribution. This means that the medicine can be delivered more accurately to the target tissue.

Ethernabe's proprietary mRNA chemistry platform technology allows for sequence engineering of mRNA constructs. This ensures optimal mRNA translation efficiency and maximal mRNA stability. The sequence engineering can be adjusted to enable immune silent or immune-stimulatory mRNA. Additionally, constructs can be optimized for improved tissue specific expression.

Ethernabe's revenue is generated through their partnerships with pharma and biotech companies, as well as through the continuation of their pipeline products. These include IV administered HPC16+ cancer treatment and an intra-tumoral platform containing a proprietary immune-activating mix.

The company also has a cGMP accredited RNA production facility in Niel, Belgium, where they have over 5 years of GMP RNA production experience and more than 30 years of manufacturing research grade RNA.

Keywords: RNA technology, Pharma and Biotech partnership, mRNA chemistry, LNP formulation, Process Technology, Biodistribution, Sequence Engineering, Pipeline Products, cGMP accredited, RNA production.